ArticleJournal of virology1997
Effect of the E4 region on the persistence of transgene expression from adenovirus vectors.
Article in Journal of virology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 189 citations in OpenAlex.
- Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus.The Journal of clinical investigation · 1999Trial
- Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors.International journal of molecular sciences · 2021Review
- Suppression of leaky expression of adenovirus genes by insertion of microRNA-targeted sequences in the replication-incompetent adenovirus vector genome.Molecular therapy. Methods & clinical development · 2014Article
- Inhalation of nebulized perfluorochemical enhances recombinant adenovirus and adeno-associated virus-mediated gene expression in lung epithelium.Human gene therapy methods · 2012Article
- Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances.Biochimica et biophysica acta · 2007Review
- Gene therapy in cardiac arrhythmias.Indian pacing and electrophysiology journal · 2006Article
- Gutless adenovirus: last-generation adenovirus for gene therapy.Gene therapy · 2005Review
- Article
- Novel molecular approaches to cystic fibrosis gene therapy.The Biochemical journal · 2005Review
- Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease.Gene therapy · 2004Article
- Transcription-controlled gene therapy against tumor angiogenesis.The Journal of clinical investigation · 2004Article
- Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States.Clinical and diagnostic laboratory immunology · 2004Article
- Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.Gene therapy · 2002Article
- Optimisation of real-time quantitative RT-PCR for the evaluation of non-viral mediated gene transfer to the airways.Gene therapy · 2002Article
- Variables affecting in vivo performance of high-capacity adenovirus vectors.Journal of virology · 2002Article
- Role for the adenovirus IVa2 protein in packaging of viral DNA.Journal of virology · 2001Article
- Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1alpha promoter.Gene therapy · 2001Article
- Adenovirus-mediated gene transfer to orthotopic hepatocellular carcinomas in athymic nude mice.Cancer gene therapy · 2001Article
- Viral and cellular factors that target the promyelocytic leukemia oncogenic domains strongly activate a glucocorticoid-responsive promoter.Journal of virology · 2001Article
- "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung.Journal of virology · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The utility of adenovirus vectors for gene therapy is limited by the transience of expression that has been observed in various in vivo models. Immunological responses to viral targets can eliminate transduced cells and cause the loss of transgene expression. We previously described the characterization of an E4 modified adenovirus, Ad2E4ORF6, which is replication defective in cotton rats. We reasoned that gene transfer vectors based on Ad2E4ORF6 would have a reduced potential for viral gene expression in vivo which might be beneficial for achieving persistence of transgene expression. E1 replacement vectors expressing the cystic fibrosis transmembrane regulator or beta-galactosidase were constructed as series of vectors that differed with respect to the E4 region. Vectors containing a wild-type E4 region, E4 open reading frame 6, or a complete E4 deletion were compared in the lungs of BALB/c mice for persistence of expression. Results obtained with nude mice indicate that nonimmunological factors have a major influence on the longevity of transgene expression. Expression was transient from the E1a promoter with all vectors but persisted from the cytomegalovirus promoter only with a vector containing a wild-type E4 region. Transience of expression did not correlate with the disappearance of vector DNA, suggesting that promoter down-regulation may be involved. Coinfection studies indicate an E4 product(s) could be supplied in trans to allow persistent expression from the cytomegalovirus promoter. In summary, the choice of promoter is important for achieving persistence of expression; in addition, some promoters are highly influenced by the context of the vector backbone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.